Literature DB >> 7536024

Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase.

M Maliepaard1, A Wolfs, S E Groot, N J de Mol, L H Janssen.   

Abstract

We report DNA interstrand cross-linking caused by the anti-tumour indoloquinone EO9 following reductive activation with purified rat liver DT-diaphorase or xanthine oxidase. Reduction was a necessary event for cross-linking to occur. DNA cross-link formation by EO9 following DT-diaphorase reduction was completely inhibited by addition 10 microM dicoumarol, whereas only a minor effect of dicoumarol on xanthine oxidase-mediated DNA cross-linking by EO9 was observed. DNA cross-linking was pH dependent, with increasing cross-link formation from pH 5.5 to 7.0 for both DT-diaphorase and xanthine oxidase mediated reactions. Also, conversion of EO9 upon reduction was pH dependent. However, in contrast to DNA cross-linking, conversion rates of EO9 decreased at higher pH. EO9 was shown to be more efficient in DNA cross-linking than mitomycin C under identical conditions, using both DT-diaphorase and xanthine oxidase reductive activation at pH 5.5 and 7.0. This study indicates that the anti-tumour activity of EO9 may be at least partly mediated by interstrand DNA cross-link formation, and that various reducing enzymes may be important for activation of EO9 in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536024      PMCID: PMC2033736          DOI: 10.1038/bjc.1995.161

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  17 in total

1.  One-electron transfer reactions in biochemical systems. VII. Two types of electron outlets in milk xanthine oxidase.

Authors:  M Nakamura; I Yamazaki
Journal:  Biochim Biophys Acta       Date:  1973-12-19

2.  Purification by cibacron blue F3GA dye affinity chromatography and comparison of NAD(P)H:quinone reductase (E.C.1.6.99.2) from rat liver cytosol and microsomes.

Authors:  D H Sharkis; R P Swenson
Journal:  Biochem Biophys Res Commun       Date:  1989-06-15       Impact factor: 3.575

3.  The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9.

Authors:  M I Walton; P J Smith; P Workman
Journal:  Cancer Commun       Date:  1991-07

4.  Reductive activation of potential antitumor bis(aziridinyl)benzoquinones by xanthine oxidase: competition between oxygen reduction and quinone reduction.

Authors:  K J Lusthof; W Richter; N J de Mol; L H Janssen; W Verboom; D N Reinhoudt
Journal:  Arch Biochem Biophys       Date:  1990-02-15       Impact factor: 4.013

5.  Structure-activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indoloquinones and diaziridinyl benzoquinones.

Authors:  S M Bailey; N Suggett; M I Walton; P Workman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

Review 6.  Bioreductive mechanisms.

Authors:  P Workman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

7.  High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin.

Authors:  T Cresteil; A K Jaiswal
Journal:  Biochem Pharmacol       Date:  1991-08-08       Impact factor: 5.858

Review 8.  DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C.

Authors:  D Ross; D Siegel; H Beall; A S Prakash; R T Mulcahy; N W Gibson
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

9.  The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase?

Authors:  N Robertson; I J Stratford; S Houlbrook; J Carmichael; G E Adams
Journal:  Biochem Pharmacol       Date:  1992-08-04       Impact factor: 5.858

10.  In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity.

Authors:  R M Phillips; P B Hulbert; M C Bibby; N R Sleigh; J A Double
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

View more
  5 in total

Review 1.  Enzymology of bioreductive drug activation.

Authors:  D Ross; H D Beall; D Siegel; R D Traver; D L Gustafson
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 2.  EO9 (Apaziquone): from the clinic to the laboratory and back again.

Authors:  Roger M Phillips; Hans R Hendriks; Godefridus J Peters
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

3.  Nitroxides as antioxidants: Tempol protects against EO9 cytotoxicity.

Authors:  Ayelet M Samuni; William DeGraff; Murali C Krishna; James B Mitchell
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

4.  Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9.

Authors:  S M Bailey; M D Wyatt; F Friedlos; J A Hartley; R J Knox; A D Lewis; P Workman
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9.

Authors:  G A Choudry; P A Stewart; J A Double; M R Krul; B Naylor; G M Flannigan; T K Shah; J E Brown; R M Phillips
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.